4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following research update on MicroRx, its proprietary platform for the discovery of novel live biotherapeutics and the development of its pipeline.

In May 2014, the Company started work on its proprietary platform MicroRX with the aim of developing a library of bacteria and accelerating the discovery of new live biotherapeutics from that library. As with Thetanix, 4D's candidate for paediatric Crohns and Rosburix, which is in development for Paediatric ulcerative colitis, the Company initially targeted other inflammatory and autoimmune diseases.

The Board of 4D is pleased to report that the Company's MicroRx platform has identified a number of bacteria that have demonstrated therapeutically relevant effects in pre-clinical models of rheumatoid arthritis, allergic asthma and severe, steroid resistant asthma.

David Norwood, Chairman of 4D, commented that: "Our library of bacteria is extensive, putting 4D in a world leading position in being able to continue to mine for therapeutics that could have a curative effect in a variety of important diseases with significant unmet needs. The ability of the MicroRx platform to rationally select bacteria from this library and demonstrate therapeutically relevant effects in models of disease in a matter of months is extraordinary. This is not only a significant step forward for 4D, but also the area of live biotherapeutics in general, demonstrating that the microbiome potentially has a significant role to play in disease and its treatment."